BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26577506)

  • 21. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
    Wassertheil-Smoller S; Hendrix SL; Limacher M; Heiss G; Kooperberg C; Baird A; Kotchen T; Curb JD; Black H; Rossouw JE; Aragaki A; Safford M; Stein E; Laowattana S; Mysiw WJ;
    JAMA; 2003 May; 289(20):2673-84. PubMed ID: 12771114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
    Anderson GL; Judd HL; Kaunitz AM; Barad DH; Beresford SA; Pettinger M; Liu J; McNeeley SG; Lopez AM;
    JAMA; 2003 Oct; 290(13):1739-48. PubMed ID: 14519708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen plus progestin and risk of benign proliferative breast disease.
    Rohan TE; Negassa A; Chlebowski RT; Lasser NL; McTiernan A; Schenken RS; Ginsberg M; Wassertheil-Smoller S; Page DL
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2337-43. PubMed ID: 18725513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
    Hulley S; Grady D; Bush T; Furberg C; Herrington D; Riggs B; Vittinghoff E
    JAMA; 1998 Aug; 280(7):605-13. PubMed ID: 9718051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
    Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
    JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study.
    Prentice RL; Pettinger M; Beresford SA; Wactawski-Wende J; Hubbell FA; Stefanick ML; Chlebowski RT
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1531-7. PubMed ID: 19423530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of estrogen plus progestin on health-related quality of life.
    Hays J; Ockene JK; Brunner RL; Kotchen JM; Manson JE; Patterson RE; Aragaki AK; Shumaker SA; Brzyski RG; LaCroix AZ; Granek IA; Valanis BG;
    N Engl J Med; 2003 May; 348(19):1839-54. PubMed ID: 12642637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen plus progestin and risk of venous thrombosis.
    Cushman M; Kuller LH; Prentice R; Rodabough RJ; Psaty BM; Stafford RS; Sidney S; Rosendaal FR;
    JAMA; 2004 Oct; 292(13):1573-80. PubMed ID: 15467059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial.
    Yasmeen S; Romano PS; Pettinger M; Johnson SR; Hubbell FA; Lane DS; Hendrix SL
    Obstet Gynecol; 2006 Aug; 108(2):410-9. PubMed ID: 16880313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen plus progestin and colorectal cancer in postmenopausal women.
    Chlebowski RT; Wactawski-Wende J; Ritenbaugh C; Hubbell FA; Ascensao J; Rodabough RJ; Rosenberg CA; Taylor VM; Harris R; Chen C; Adams-Campbell LL; White E;
    N Engl J Med; 2004 Mar; 350(10):991-1004. PubMed ID: 14999111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen plus progestin and the risk of coronary heart disease.
    Manson JE; Hsia J; Johnson KC; Rossouw JE; Assaf AR; Lasser NL; Trevisan M; Black HR; Heckbert SR; Detrano R; Strickland OL; Wong ND; Crouse JR; Stein E; Cushman M;
    N Engl J Med; 2003 Aug; 349(6):523-34. PubMed ID: 12904517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
    Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB
    JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy.
    Chlebowski RT; Anderson G; Pettinger M; Lane D; Langer RD; Gilligan MA; Walsh BW; Chen C; McTiernan A;
    Arch Intern Med; 2008 Feb; 168(4):370-7; quiz 345. PubMed ID: 18299491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk.
    Crandall CJ; Aragaki AK; Chlebowski RT; McTiernan A; Anderson G; Hendrix SL; Cochrane BB; Kuller LH; Cauley JA
    Arch Intern Med; 2009 Oct; 169(18):1684-91. PubMed ID: 19822825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.
    Toh S; Hernández-Díaz S; Logan R; Rossouw JE; Hernán MA
    Ann Intern Med; 2010 Feb; 152(4):211-7. PubMed ID: 20157135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer after use of estrogen plus progestin in postmenopausal women.
    Chlebowski RT; Kuller LH; Prentice RL; Stefanick ML; Manson JE; Gass M; Aragaki AK; Ockene JK; Lane DS; Sarto GE; Rajkovic A; Schenken R; Hendrix SL; Ravdin PM; Rohan TE; Yasmeen S; Anderson G;
    N Engl J Med; 2009 Feb; 360(6):573-87. PubMed ID: 19196674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.
    Anderson GL; Chlebowski RT; Aragaki AK; Kuller LH; Manson JE; Gass M; Bluhm E; Connelly S; Hubbell FA; Lane D; Martin L; Ockene J; Rohan T; Schenken R; Wactawski-Wende J
    Lancet Oncol; 2012 May; 13(5):476-86. PubMed ID: 22401913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.